JGC
TVTX icon

J. Goldman & Co’s Travere Therapeutics TVTX Stock Holding History

J. Goldman & Co’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,100
Closed -$1.04M – 880
2025
Q4 		$1.04M Sell
27,100
-26,900
-50% -$875K 0.03% 383
2025
Q3 		$1.29M Buy
+54,000
New +$1.02M 0.03% 312

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

J. Goldman & Co's TVTX Position: Q1 2025 in Review

J. Goldman & Co sold out of Travere Therapeutics (TVTX) in Q1 2025, closing a stake of 181,174 shares — an estimated $3.16M sold.

J. Goldman & Co first reported a position in TVTX in Q1 2015 and held it in 9 quarters. The position peaked at $4.55M in Q1 2019. 218 funds tracked by Wall St. Rank hold TVTX as of Q1 2025.

  • J. Goldman & Co reported no remaining Travere Therapeutics position as of Q1 2025 after selling out during the quarter.
  • J. Goldman & Co sold 181,174 Travere Therapeutics shares in Q1 2025, an estimated $3.16M.
  • J. Goldman & Co first reported a position in Travere Therapeutics in Q1 2015 and held it in 9 quarters.
  • J. Goldman & Co's Travere Therapeutics position peaked at $4.55M in Q1 2019.
  • 218 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2025.

Based on J. Goldman & Co's 13F filing for Q1 2025, filed 15 May 2025.